MedTrace Logo

Ivermectin Versus Albendazole for Chronic Strongyloidiasis

NCT00765024 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2017-09-07

No results posted yet for this study

Summary

A prospective controlled trial to compare the efficacy and safety of 7-day albendazole, single dose ivermectin, and 2-single dose ivermectin in 72 patients with chronic strongyloidiasis will be conducted at Siriraj Hospital, Bangkok, Thailand.

Conditions

  • Chronic Strongyloidiasis

Interventions

DRUG

Ivermectin

single dose of 200 mcg/kg

DRUG

ivermectin

two single dose of 200mcg/kg in 2 weeks

DRUG

Albendazole

Albendazole 7 days

Sponsors & Collaborators

  • Atlantic Laboratory Ltd

    collaborator UNKNOWN

  • Mahidol University

    lead OTHER

Principal Investigators

  • Yupin Suputtamongkol, MD · Mahidol University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2010-04-30
Completion
2010-04-30

Countries

  • Thailand

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00765024 on ClinicalTrials.gov